NCT04587492 is a clinical trial of Nusinersen in Spinal Muscular Atrophy, sponsored by University Medical Centre Ljubljana.

Who is sponsoring NCT04587492?

NCT04587492 is sponsored by University Medical Centre Ljubljana.

What drugs are being tested in NCT04587492?

Interventions in NCT04587492: Nusinersen.

What condition does NCT04587492 study?

NCT04587492 studies Spinal Muscular Atrophy.

Is NCT04587492 still recruiting?

NCT04587492 is currently completed. Last updated 10 November 2022.

Last reviewed 2022-11-10 · How we verify

NCT04587492

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metabolomics of Children With SMA

Completed Last updated 10 November 2022

What this trial tests

trial testing Nusinersen in Spinal Muscular Atrophy in 35 participants. Completed in 30 September 2020.

Timeline

1 January 2017

Primary endpoint
30 September 2020

30 September 2020

Quick facts

Lead sponsor	University Medical Centre Ljubljana
Status	Completed
Study type	OBSERVATIONAL
Enrollment	35
Start date	1 January 2017
Primary completion	30 September 2020
Estimated completion	30 September 2020
Sites	2 locations across Slovenia

Drugs / interventions tested

Nusinersen (NUSINERSEN) — full drug profile →

Conditions studied

Spinal Muscular Atrophy — all drugs for Spinal Muscular Atrophy →

Sponsor

University Medical Centre Ljubljana

Who can join

Under 21, any sex, with Spinal Muscular Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the proposed project is to evaluate whether the metabolome of patients with spinal muscular atrophy (SMA) before the initiation of treatment with nusinersen differs from the metabolome of healthy individuals and whether it changes 14 months after treatment with nusinersen.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Spinal Muscular Atrophy after Nusinersen Therapy: Improved Physiology in Pediatric Patients with No Significant Change in Urine, Serum, and Liquor 1H-NMR Metabolomes in Comparison to an Age-Matched, Healthy Cohort.
Deutsch L, Osredkar D, Plavec J, Stres B. · · 2021 · cited 26× · PMID 33808177 · DOI 10.3390/metabo11040206
Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical-Experimental, and Real-World Evidence.
Crisafulli S, Boccanegra B, Vitturi G, Trifirò G, et al · · 2023 · cited 11× · PMID 37891814 · DOI 10.3390/brainsci13101446

Verify or expand the search:

Other trials of Nusinersen

Trials testing the same drug.

NCT06555419 — A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pe · Phase 1 · recruiting
NCT04576494 — Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms) · NA · completed
NCT05067790 — A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spina · Phase 3 · active not recruiting
NCT05187260 — Antisense Oligonucleotide for Spinal Muscular Atrophy · unknown
NCT04729907 — A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants · Phase 3 · active not recruiting

Other recruiting trials for Spinal Muscular Atrophy

Currently open trials in the same condition.

NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT06955897 — Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA · recruiting
NCT06396325 — A Registry Based Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents With · NA · recruiting
NCT06288230 — An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy · Phase 1, PHASE2 · recruiting
NCT06321965 — Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy · NA · recruiting

Other University Medical Centre Ljubljana trials

Trials by the same sponsor.

NCT07466472 — Image-Guided Central Catheter Insertion With Concurrent Assessment of Vascular Wall Integrity · not yet recruiting
NCT07446244 — Catheter Ablation of Advanced Forms of Atrial Fibrillation · NA · enrolling by invitation
NCT07109076 — Effect of Immediate Skin-to-Skin Contact on Neonatal Heart Rate Variability After Cesarean Secton · NA · recruiting
NCT07354880 — Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease · Phase 4 · not yet recruiting
NCT07496736 — Post-exposure Influenza Prophylaxis in a Hospital Setting · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04587492 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Centre Ljubljana
Last refreshed: 10 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04587492.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing